<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01426100</url>
  </required_header>
  <id_info>
    <org_study_id>130HT11B</org_study_id>
    <nct_id>NCT01426100</nct_id>
  </id_info>
  <brief_title>CKD-828 Telmisartan Non-Responder Trial</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of Telmisartan and S-Amlodipine(CKD-828) Versus Telmisartan Monotherapy in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <brief_summary>
    <textblock>
      The aim of the present study is to evaluate the efficacy and safety of two dose combination
      of Telmisartan/S-Amlodipine (40/2.5mg and 40/5mg) compared with telmisartan monotherapy
      (80mg) in hypertensive patients inadequately controlled by telmisartan monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Sitting Diastolic Blood Pressure (MSDBP)</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Sitting Diastolic Blood Pressure (MSDBP)</measure>
    <time_frame>After 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sitting Systolic Blood Pressure (MSSBP)</measure>
    <time_frame>After 4 weeks and 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>After 4 weeks and 8 weeks of treatment</time_frame>
    <description>Reduction of SBP ≥ 20mmHg, DBP ≥ 10mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control rate</measure>
    <time_frame>After 4 weeks and 8 weeks of treatment</time_frame>
    <description>Reduction SBP &lt; 140mmHg, DBP &lt; 90mmHg</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>CKD-828 40/2.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-828 40/5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan 80mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-828 40/2.5mg</intervention_name>
    <description>Fixed dose combination of Telmisartan 40mg and S-Amlodipine 2.5mg</description>
    <arm_group_label>CKD-828 40/2.5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-828 40/5mg</intervention_name>
    <description>Fixed dose combination of Telmisartan 40mg and S-Amlidioine 5mg</description>
    <arm_group_label>CKD-828 40/5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 80mg</intervention_name>
    <description>Telmisartan 80mg monotherapy</description>
    <arm_group_label>Telmisartan 80mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 years or older

          -  diagnosis of essential hypertension and blood pressure not adequately
             controlled(inadequate control defined as seated diastolic blood pressure(DBP)&gt;= 90mmHg
             if on existing antihypertensive treatment of seated DBP &gt;= 100mmHg if treatment naive)

          -  failure to respond to four weeks treatment with telmisartan 40mg(failure to respond
             defined as seated DBP &gt;= 90mmHg)

          -  willing and able to provide written informed consent

        Exclusion Criteria:

          -  mean seated DBP &gt;= 120mmHg and/or mean seated SBP &gt;= 200mmHg during run-in treatment
             or mean seated DBP &gt;= 120mmHg and/or mean seated SBP &gt;= 180mmHg at the randomization
             visit

          -  known or suspected secondary hypertension(ex. aortic coarctation, Primary
             hyperaldosteronism, renal artery stenosis, pheochromocytoma)

          -  has severe heart disease(Heart failure NYHA functional class 3, 4), unstable angina or
             myocardial infarction, arrhythmia within the past three months

          -  has cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6
             months

          -  Type I Diabetes Mellitus, Type II Diabetes Mellitus with poor glucose control as
             defined by fasting glucosylated hemoglobin(HbA1c) &gt; 8%

          -  nown severe or malignant retinopathy

          -  hepatic or renal dysfunction as defined by the following laboratory parameters:
             AST/ALT &gt; UNL X 2, serum creatinine &gt; UNL X 1.5

          -  acute or chronic inflammatory status need to treatment

          -  need to additional antihypertensive drugs during the study

          -  need to concomitant medications known to affect blood pressure during the study

          -  history of angioedema related to ACE inhibitors or Angiotensin II Receptor Blockers

          -  known hypersensitivity related to either study drug

          -  history of drug or alcohol dependency within 6 months

          -  any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism, or excretion of investigational products(ex.
             gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bypass,
             active inflammatory bowel syndrome within 12 months prior to screening, gastric ulcers
             need to treatment, gastrointestinal/rectal bleeding, impaired pancreatic function such
             as pancreatitis, obstructions of the urinary tract or difficulty in voiding

          -  administration of other study drugs within 30 days prior to randomization

          -  premenopausal women(last menstruation &lt; 1year) not using adequate contraception,
             pregnant or breast-feeding

          -  history of malignancy including leukemia and lymphoma within the past 5 years

          -  in investigator's judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kandong Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DonGuk University Ilsan Hospital</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Health Insurance Corporation Ilsan Hospital</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Inchon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bundang Cha Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital, The catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2011</study_first_submitted>
  <study_first_submitted_qc>August 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2011</study_first_posted>
  <last_update_submitted>September 11, 2012</last_update_submitted>
  <last_update_submitted_qc>September 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD-828</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Primary Hypertension</keyword>
  <keyword>S-Amlodipine</keyword>
  <keyword>Telmisartan</keyword>
  <keyword>Amlodipine</keyword>
  <keyword>Non-Responder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

